Clinical-stage neuromod developer NeoSync said today it closed a $13 million Series D financing round to support a registration trial of its NeoSync-EEG Synchronized transcranial magnetic stimulation technology. The Boston-based company said its Nest technology is designed to deliver low-energy, alternative magnetic field stimulation to treat individuals with treatment resistant depression. NeoSync said the round […]